德国拜耳利伐沙班在中国上市了吗？

Germany's Bayer has approved it for the prevention of venous thrombosis (VTE) in adult patients undergoing hip or knee replacement surgery; and for the treatment of deep vein thrombosis (DVT) in adults to reduce the risk of DVT recurrence and pulmonary embolism (PE) after acute DVT.

Atrial fibrillation is a common heart rhythm disorder, with a prevalence of up to 10% in people over the age of 75. The blood of patients with atrial fibrillation is prone to stasis in the atria and the formation of thrombus, and the detachment of the thrombus can lead to stroke.

Germany's Bayer Rivaroxaban has been approved and recommended for use in adult patients with non-valvular atrial fibrillation to reduce the risk of stroke and systemic embolism. The efficacy of rivaroxaban is not inferior to warfarin, the incidence of intracranial hemorrhage is lower than warfarin, and routine monitoring of anticoagulation intensity is not required.

Bayer is a large global company with core competencies in health care, agriculture and high-tech raw materials. As an innovative company, it has a tendency to delve deeper into research fields. Bayer designs products and services that benefit people and improve their quality of life. At the same time, the Bayer Group is committed to creating value through innovation, development and strong profitability.

Rivaroxaban is a direct factor Xa inhibitor. Is Bayer's rivaroxaban available in China?

In 2009, it was approved for marketing in China for the prevention and treatment of venous thromboembolic disease and the prevention of stroke in non-valvular atrial fibrillation.

Recommended related hot articles: /newsDetail/93939.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.